Idiopathic Membranous Nephropathy Market to Register Immense Growth at a CAGR of 12% During the Study Period (2019-2032), Predicts DelveInsight

As potential therapies are being investigated to manage idiopathic membranous nephropathy, it is safe to predict that the idiopathic membranous nephropathy market will experience significant reconstitution during 2023–2032. However, the challenges of the rigid and burdensome structure of regulatory authorities will decide the fate of all these pipeline therapies and the impact they will have on overall revenue generation.

LAS VEGAS, June 1, 2023 /PRNewswire/ -- DelveInsight's Idiopathic Membranous Nephropathy Market Insights report includes a comprehensive understanding of current treatment practices, idiopathic membranous nephropathy emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan] and China.

Key Takeaways from the Idiopathic Membranous Nephropathy Market Report

• As per DelveInsight analysis, the idiopathic membranous nephropathy market size in the 7MM + China was approximately USD 220 million in 2022.
• According to the assessment done by DelveInsight, the estimated total prevalent idiopathic membranous nephropathy cases in the 7MM + China were approximately 380K in 2022. 
• Leading idiopathic membranous nephropathy companies such as Hoffmann-La Roche, MorphoSys, Cerium Pharmaceuticals, BeiGene, Reistone Biopharma, Eternity Bioscience, GlaxoSmithKline, ValenzaBio, ACELYRIN, and others are developing novel Idiopathic Membranous Nephropathy drugs that can be available in the Idiopathic Membranous Nephropathy market in the coming years.
• The promising idiopathic membranous nephropathy therapies in the pipeline include GAZYVA (obinutuzumab), MOR202 (felzartamab), SNP-ACTH (1-39) Gel, BRUKINSA (zanubrutinib), SHR1459 (edralbrutinib), BENLYSTA (belimumab), VB119, and others.

Discover which therapies are expected to grab the major idiopathic membranous nephropathy market share @ Idiopathic Membranous Nephropathy Market Report

Idiopathic Membranous Nephropathy Overview

Membranous nephropathy is a kidney disease affecting the kidney's filters. It causes a rise in protein in the urine, impaired renal function, and edoema. It's also known as membranous glomerulopathy. Membranous nephropathy is a rare disease that affects the renal glomerulus, specifically the podocytes, which play an important role in limiting the permeability of the kidney to proteins. The most common membranous nephropathy symptom is swelling, often known as edema. This might range from minor to severe. Most patients have some edema, which is generally the initial symptom. Swelling in membranous nephropathy is usually slow compared to other disorders that cause protein in the urine and nephrotic syndrome, but it can sometimes be sudden. It usually begins in the feet, ankles, or legs, although it can develop elsewhere in the body, including the abdomen, hands, arms, and face. Protein in the urine is frequently used to make membranous nephropathy diagnosis. A blood test, a kidney biopsy, optical microscopy, immunofluorescence, electron microscopy, and antibody-guided diagnostics are also conducted.

Idiopathic Membranous Nephropathy Epidemiology Segmentation

DelveInsight estimates that there were approximately 380K prevalent cases of idiopathic membranous nephropathy in the 7MM in 2022.

China contributed to the largest prevalent population of idiopathic membranous nephropathy, acquiring ~82% of the 7MM and China in 2022. Whereas EU4 and the UK for ~6%, and Japan accounted for ~5% of the total population share, in 2022.

The idiopathic membranous nephropathy market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM + China segmented into:

• Idiopathic Membranous Nephropathy Prevalence
• Idiopathic Membranous Nephropathy Prevalence by Antigens

Idiopathic Membranous Nephropathy Treatment Market 

There is no cure for either primary or secondary membranous nephropathy. When treating individuals with the illness, doctors usually take a symptomatic approach and aim to improve the patient's immune system. Patients are put on supportive care as soon as the diagnosis is confirmed, regardless of the underlying cause, and this is continued throughout the duration of the condition. It includes careful blood pressure control, angiotensin-converting enzyme inhibitor/angiotensin receptor blocker therapy to reduce proteinuria and increase the chances of spontaneous remission, statins for hyperlipidemia, salt restriction, diuretics to control edoema, and a low protein diet to allow for the replacement of urinary protein losses. In recent research, alkylating drugs used in combination with corticosteroids produced positive results in membranous nephropathy patients.

Immunosuppressive therapy (such as steroids and alkylating agents, calcineurin inhibitors (CNIs), and rituximab) are among the medications used to treat membranous nephropathy patients. Alkylating drugs, steroids, and calcineurin inhibitors (CNIs) have formed the foundation of immunosuppression and immunosuppressive medications. Though they are partially effective in reducing proteinuria in membranous nephropathy patients, they have also been linked to greater relapse rates and significant adverse responses. 

To know more about idiopathic membranous nephropathy treatment guidelines, visit @ Idiopathic Membranous Nephropathy Management 

Idiopathic Membranous Nephropathy Pipeline Therapies and Key Companies

• GAZYVA (obinutuzumab): Hoffmann-La Roche
• MOR202 (felzartamab): MorphoSys
• SNP-ACTH (1-39) Gel: Cerium Pharmaceuticals
• BRUKINSA (zanubrutinib): BeiGene
• SHR1459 (edralbrutinib): Reistone Biopharma/Eternity Bioscience
• BENLYSTA (belimumab): GlaxoSmithKline
• VB119: ValenzaBio/ACELYRIN

Learn more about the FDA-approved drugs for idiopathic membranous nephropathy @ Drugs for Idiopathic Membranous Nephropathy Treatment 

Idiopathic Membranous Nephropathy Market Dynamics

The dynamics of the idiopathic membranous nephropathy market are expected to change in the coming years. Increased research activities and the discovery of new biomarkers and therapeutic targets, will result in the development of improved medicines in the future. Although rituximab is effective, patients can acquire medication resistance over time. Roche's Obinutuzumab is being developed with improved efficacy, which will aid in overcoming the limits of current therapy.

Moreover, the rapid incidence of progression and remission in membranous nephropathy patients provides pharmaceutical companies with an opportunity to develop therapies to address the inadequacies and capture a largely untapped idiopathic membranous nephropathy market. Only a few drugs, such as Obinutuzumab, are in the latter stages of development. As a result, it opens the door for additional pharmaceutical companies to enter the idiopathic membranous nephropathy market with fresh therapeutic choices.

However, several factors may impede the growth of the idiopathic membranous nephropathy market. Due to knowledge gaps and a lack of clarity about membranous nephropathy pathology, there is an urgent scarcity of large-scale clinical studies assessing therapy alternatives in membranous nephropathy. The outcomes of idiopathic membranous nephropathy treatment candidates that are in various stages of clinical development and are expected to be launched are not available. As a result, establishing the safety and efficacy of these medications is difficult.

Moreover, as membranous nephropathy is a rare indication, it is often overshadowed by more common and fatal renal diseases, thereby influencing the whole research and development process. Almost 30% of membranous nephropathy cases develop into ESRD, yet the therapeutic landscape is devoid of recognized medicines, leading to a high fatality rate.

Scope of the Idiopathic Membranous Nephropathy Market Report

• Therapeutic Assessment: Idiopathic Membranous Nephropathy current marketed and emerging therapies
• Idiopathic Membranous Nephropathy Market Dynamics: Attribute Analysis of Emerging Idiopathic Membranous Nephropathy Drugs
• Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
• Unmet Needs, KOL's views, Analyst's views, Idiopathic Membranous Nephropathy Market Access and Reimbursement

Discover more about idiopathic membranous nephropathy drugs in development @ Idiopathic Membranous Nephropathy Clinical Trials

Table of Contents

Related Reports

Idiopathic Membranous Nephropathy Epidemiology Forecast

Idiopathic Membranous Nephropathy Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, and idiopathic membranous nephropathy epidemiology trends.

Nephrotic Syndrome Pipeline

Nephrotic Syndrome Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key nephrotic syndrome companies, including GlaxoSmithKline, Goldfinch Bio, Inc., Travere Therapeutics, Inc., Aurinia Pharmaceuticals, Bristol-Myers Squibb, ChemoCentryx, SynAct Pharma AB, among others.

Nephrotic Syndrome Market

Nephrotic Syndrome Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key nephrotic syndrome companies, including GlaxoSmithKline, Goldfinch Bio, Inc., Travere Therapeutics, Inc., Aurinia Pharmaceuticals, Bristol-Myers Squibb, ChemoCentryx, SynAct Pharma AB, among others.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Contact Us
Shruti Thakur 
info@delveinsight.com 
+1(919)321-6187 
www.delveinsight.com

Logo: https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg